Zahnreich Sebastian, Ebersberger Anne, Karle Heiko, Kaina Bernd, Schmidberger Heinz
a Radiation Oncology and Radiation Therapy and.
b Toxicology, University Medical Center Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Radiat Res. 2016 Nov;186(5):508-519. doi: 10.1667/RR14475.1. Epub 2016 Oct 27.
The goal of this study was to determine whether the quantification of radiation biomarkers in peripheral leukocytes of 111 breast cancer patients after adjuvant treatment with different modalities of three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) revealed any difference in the patients' radiation burden by out-of-field doses and an associated risk of second malignancies. Whole-breast radiation therapy was performed by 3D-CRT using either a hard wedge (n = 32) or a virtual wedge (n = 49) at dose rates of 3 and 6 Gy per min each. Patients receiving additional radiotherapy to lymph nodes were treated by 3D-CRT (n = 21) or IMRT (n = 9). DNA damage was measured as γ-H2AX foci (n = 111) and as unstable chromosomal aberrations (n = 15) in leukocytes drawn 30 min and 24 h after the first radiation fraction, respectively. The individual basal yield and radiation sensitivity ex vivo were assessed in leukocytes obtained before the first treatment. After radiation therapy, the average rate of γ-H2AX foci and chromosomal aberrations per leukocyte were dependent on multiple parameters of irradiation: the treatment volume, the administered equivalent whole-body dose, the number of monitor units and the beam-on time. Different modalities of radiation therapy caused significant variations in the levels of both radiation biomarkers irrespective of the treatment volume and administered dose, and in particular, a twofold higher rate after IMRT compared to 3D-CRT. Any deviation in biomarker response between radiation therapy techniques was directed by a linear dependence on the absolute beam-on time. However, the dispersion of γ-H2AX foci in peripheral leukocytes after radiation therapy correlated very well with the relative distribution of dose in the whole-body volume for each radiation therapy technique. In conclusion, the induction of radiation biomarkers in leukocytes of breast cancer patients by different radiotherapy modalities is dominated by general variables of irradiation. There was no significant difference in peripheral dose exposure observed in the investigated radiation therapy techniques. Radiotherapy techniques with prolonged absolute beam-on time increase the fraction of exposed leukocytes with pronounced risks for hematologic toxicities or immunosuppressive side effects.
本研究的目的是确定在111例乳腺癌患者接受三维适形放疗(3D-CRT)或调强放疗(IMRT)的不同方式辅助治疗后,外周血白细胞中辐射生物标志物的定量分析是否能揭示患者因野外剂量导致的辐射负担差异以及继发第二原发恶性肿瘤的相关风险。全乳放疗采用3D-CRT,使用硬楔形板(n = 32)或虚拟楔形板(n = 49),剂量率分别为每分钟3 Gy和6 Gy。接受淋巴结追加放疗的患者采用3D-CRT(n = 21)或IMRT(n = 9)治疗。分别在首次放疗后30分钟和24小时采集白细胞,测量DNA损伤,以γ-H2AX焦点(n = 111)和不稳定染色体畸变(n = 15)表示。在首次治疗前采集的白细胞中评估个体基础产量和体外辐射敏感性。放疗后,每个白细胞中γ-H2AX焦点和染色体畸变的平均发生率取决于多个照射参数:治疗体积、给予的等效全身剂量、监测单位数量和照射时间。无论治疗体积和给予剂量如何,不同放疗方式均导致两种辐射生物标志物水平存在显著差异,特别是IMRT后的发生率比3D-CRT高两倍。放疗技术之间生物标志物反应的任何偏差都与绝对照射时间呈线性相关。然而,放疗后外周血白细胞中γ-H2AX焦点的离散度与每种放疗技术在全身体积中的剂量相对分布非常吻合。总之,不同放疗方式在乳腺癌患者白细胞中诱导辐射生物标志物主要受照射的一般变量影响。在所研究的放疗技术中,外周剂量暴露没有显著差异。绝对照射时间延长的放疗技术会增加暴露白细胞的比例,这些白细胞有发生血液学毒性或免疫抑制副作用的明显风险。